Martin J. Duvall
Chairman chez Oncopeptides, Inc.
Profil
Martin J.
Duvall is currently the Chairman of Oncopeptides, Inc. and a Director of Oncopeptides Incentive AB.
He was previously the Chief Executive Officer & Director of Tocagen, Inc. and the Chief Executive Officer of Oncopeptides AB.
He has also held senior positions at Merck & Co., Inc., MGI PHARMA, Inc., ARIAD Pharmaceuticals, Inc., and Abraxis BioScience, Inc. He was a Vice President at Aventis Pharmaceuticals, Inc. Mr. Duvall has a graduate degree from The Johns Hopkins University, an undergraduate degree from Muhlenberg College, and an MBA from the University of Kansas.
Postes actifs de Martin J. Duvall
| Sociétés | Poste | Début |
|---|---|---|
MGI PHARMA Biologics, Inc.
 MGI PHARMA Biologics, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA Biologics, Inc. develops and markets pharmaceutical and medical therapies. The company's products amolimogene and ZYC300 represent a breakthrough in the activition of cytotoxic cells. The company was founded in 1979 and is located in Lexington, MA | Corporate Officer/Principal | 01/11/2004 |
Oncopeptides, Inc.
 Oncopeptides, Inc. Medical/Nursing ServicesHealth Services Part of Oncopeptides AB, Oncopeptides, Inc. is a private company committed to developing therapies for difficult-to-treat hematological diseases. The company is based in Waltham, MA. Oncopeptides strives to bring hope to patients through science and innovation, and is dedicated to bringing forward new and meaningful treatment options. The company is inspired by the perseverance of patients, caregivers, and healthcare providers in their fight against cancer. Oncopeptides' focus is on the development of therapies that can make a difference in the lives of those affected by hematological diseases. | Chairman | - |
| Oncopeptides Incentive AB | Director/Board Member | - |
Anciens postes connus de Martin J. Duvall
| Sociétés | Poste | Fin |
|---|---|---|
| ONCOPEPTIDES AB | Chief Executive Officer | 15/11/2021 |
| FORTE BIOSCIENCES, INC. | Chief Executive Officer | 15/06/2020 |
| ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 26/05/2016 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/09/2011 |
MGI PHARMA, Inc.
 MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | Corporate Officer/Principal | 27/04/2011 |
Formation de Martin J. Duvall
| The Johns Hopkins University | Graduate Degree |
| Muhlenberg College | Undergraduate Degree |
| University of Kansas | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ONCOPEPTIDES AB | Health Technology |
| Entreprise privées | 8 |
|---|---|
MGI PHARMA, Inc.
MGI PHARMA, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA, INC. develops, manufactures & markets pharmaceutical and medical products for therapeutic markets. The company's products include Aloxi injection, Dacogen, Gliadel water, Hexalen capsules, and Salagen Tablets. It has alliances with Helsinn Healthcare SA, Kissei Pharmaceutical Co. Ltd., Dainippon Pharmaceutical Co. Ltd., Pfizer, Inc. and Novartis Pharma AG. The company was founded in 1979 and is headquartered in Bloomington, MN. | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
Tocagen, Inc.
 Tocagen, Inc. BiotechnologyHealth Technology Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA. | Health Technology |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
MGI PHARMA Biologics, Inc.
MGI PHARMA Biologics, Inc. Pharmaceuticals: MajorHealth Technology MGI PHARMA Biologics, Inc. develops and markets pharmaceutical and medical therapies. The company's products amolimogene and ZYC300 represent a breakthrough in the activition of cytotoxic cells. The company was founded in 1979 and is located in Lexington, MA | Health Technology |
| Oncopeptides Incentive AB | |
Oncopeptides, Inc.
Oncopeptides, Inc. Medical/Nursing ServicesHealth Services Part of Oncopeptides AB, Oncopeptides, Inc. is a private company committed to developing therapies for difficult-to-treat hematological diseases. The company is based in Waltham, MA. Oncopeptides strives to bring hope to patients through science and innovation, and is dedicated to bringing forward new and meaningful treatment options. The company is inspired by the perseverance of patients, caregivers, and healthcare providers in their fight against cancer. Oncopeptides' focus is on the development of therapies that can make a difference in the lives of those affected by hematological diseases. | Health Services |
